AZD4635

Other Medications

Description

AZD4635 is an investigational drug currently being studied in clinical trials for various advanced solid cancers, including colorectal cancer. It is being evaluated in Phase 1 trials to determine its safety, how it's processed by the body (pharmacokinetics), and if it shows early signs of effectiveness (preliminary anti-tumor activity). These trials involve different ways of giving the drug, including capsules and a nanoparticle suspension. AZD4635 is being tested both alone (monotherapy) and in combination with other cancer treatments like durvalumab, oleclumab, and docetaxel. The trials are designed to find the best dose and understand how patients respond to the drug.

Mechanism of Action

AZD4635 is being investigated as a potential treatment for advanced cancers. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is being tested alone and in combination with other therapies to see how it affects cancer cells and the body's response.

Side Effects

As AZD4635 is an investigational drug in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. The primary goal of Phase 1 trials is to assess safety and determine the highest dose that can be given without unacceptable side effects (the Recommended Phase 2 Dose). Information about specific side effects observed in these trials is not yet widely available But common side effects for drugs in this class or used in combination (like chemotherapy or immunotherapy) can include fatigue Nausea Diarrhea Skin reactions And effects on blood counts. More detailed side effect information will become available as trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02740985 Phase 1
Archived
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
United States